Tofacitinib probably leads to lower withdrawals due to adverse events (5 mg/10 mg) compared with placebo (moderate certainty).
It is very uncertain whether antivirals plus corticosteroids changes adverse events № of participants: 656 (2 RCTs) compared with corticosteroids plus placebo or no treatment (AS versus OS) (very low certainty).
The review found no eligible studies for this question.
Two infusions of natalizumab (300 mg or 3 mg/kg) showed no clear difference in withdrawal due to adverse events up to week 12 compared with placebo (low certainty).
Two infusions of natalizumab (6 mg/kg) showed no clear difference in withdrawal due to adverse events up to week 12 compared with placebo (low certainty).
Three infusions of natalizumab (300 mg) and two infusions of… showed no clear difference in withdrawal due to adverse events up to week 10 compared with placebo and two infusions of infliximab (low certainty).
One infusion of natalizumab (300 mg or 3 mg/kg) showed no clear difference in withdrawal due to adverse events up to week 12 compared with placebo (low certainty).
It is very uncertain whether celecoxib changes number experiencing any serious adverse events compared with placebo (very low certainty).
It is very uncertain whether botulinum neurotoxin B changes proportion of participants with adverse events compared with placebo (very low certainty).
Topical acyclovir showed no clear difference in adverse events ‐ pain with topical application compared with placebo (low certainty).
Recombinant human factor VII activated showed no clear difference in serious adverse events by total adverse events compared with placebo (high certainty).
Antidepressants probably leads to higher adverse events ‐ Withdrawn for medical reasons compared with placebo (moderate certainty).
Antidepressants probably leads to higher adverse events ‐ Withdrawn for medical reasons compared with placebo according to any definition (moderate certainty).
Antifungal drugs absorbed from GI tract (fluconazole, ketoconazole,… showed no clear difference in toxicity (adverse events probably due to drug) compared with placebo or no treatment; GRADE not reported.
Anticoagulant agent may leads to lower adverse events (hospital records/every 6 weeks) compared with placebo (low certainty).
The review found no eligible studies for this question.
Galantamine probably leads to higher adverse events (all adverse events) at 26 weeks compared with placebo (moderate certainty).
Donepezil 10 mg leads to higher adverse events (all adverse events) at 24 weeks compared with placebo (high certainty).
Vitamin A leads to higher adverse events: minor gastrointestinal symptoms compared with placebo (high certainty).